Filing Details
- Accession Number:
- 0001209191-17-025766
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-04-05 17:26:24
- Reporting Period:
- 2017-04-04
- Filing Date:
- 2017-04-05
- Accepted Time:
- 2017-04-05 17:26:24
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1016169 | Antares Pharma Inc. | ATRS | Surgical & Medical Instruments & Apparatus (3841) | 411350192 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1054942 | F Robert Apple | C/O Antares Pharma, Inc. 100 Princeton South, Suite 300 Ewing NJ 08628 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-04-04 | 37,000 | $1.65 | 927,002 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-04-04 | 37,000 | $3.00 | 890,002 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2017-04-05 | 3,000 | $1.65 | 893,002 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-04-05 | 3,000 | $3.00 | 890,002 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2017-04-04 | 37,000 | $0.00 | 37,000 | $1.65 |
Common Stock | Stock Option (right to buy) | Disposition | 2017-04-05 | 3,000 | $0.00 | 3,000 | $1.65 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
3,000 | 2017-05-10 | No | 4 | M | Direct | |
0 | 2017-05-10 | No | 4 | M | Direct |
Footnotes
- The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. The exercised stock option reported on this Form 4 was due to expire on May 10, 2017.
- The options vested and became exercisable in equal quarterly installments over three years following the grant date of May 10, 2007.